Literature DB >> 9409583

Cytoablative therapy with combined resection and cryosurgery for limited bilobar hepatic colorectal metastases.

L B Johnson1, T L Krebs, D Van Echo, J S Plotkin, M Njoku, J J Wong, B D Daly, P C Kuo.   

Abstract

BACKGROUND: Cryosurgery can be employed in patients with unresectable hepatic metastases when the tumor size and the number of metastases are limited. However, local recurrence can result from incomplete ablation. We proposed a trial of complete cytoablation with a combined approach of cryosurgery and hepatic resection for patients with bilobar hepatic metastases.
METHODS: Seven patients underwent cryosurgery alone (CRYO). Seven additional patients underwent combined resection and cryosurgery (CRYO+RES) for bilobar metastases.
RESULTS: In the CRYO group, 5 of 7 patients had at least one centrally located tumor. All 5 of these patients had early recurrence at the site of ablation. In the CRYO+RES group complete ablation was achieved in 7 of 7. Two (28.6%) of these patients developed local recurrence.
CONCLUSION: Cytoablation of hepatic metastases can be safely achieved with combined hepatic resection and cryosurgery in selected patients. Long-term survival data are necessary before advocating widespread application of this approach.

Entities:  

Mesh:

Year:  1997        PMID: 9409583     DOI: 10.1016/s0002-9610(97)00176-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Rationale for the combination of cryoablation with surgical resection of hepatic tumors.

Authors:  C Cha; F T Lee; L F Rikkers; J E Niederhuber; B T Nguyen; D M Mahvi
Journal:  J Gastrointest Surg       Date:  2001 Mar-Apr       Impact factor: 3.452

2.  Complete shutdown of microvascular perfusion upon hepatic cryothermia is critically dependent on local tissue temperature.

Authors:  G Schüder; G Pistorius; M Fehringer; G Feifel; M D Menger; B Vollmar
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.